Antibodies against tumor surface antigens

Details Antibodies against tumor surface antigens Antibodies against tumor surface antigens

2007-05-29

2009-12-01

Helms, Larry R. (Department: 1643)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C424S130100

Reexamination Certificate

active

07626011

ABSTRACT:
The present invention relates to improved antibodies against tumor surface antigens and their use in the treatment of tumors. Of particular interest are highly stable, humanized, high affinity antibodies against carcinoembryonic antigen (CEA), especially the antibody we have termed sm3E, which is derived from the scFv antibody MFE-23. Such antibodies have the potential for improved therapeutic efficacy.

REFERENCES:
patent: 5876691 (1999-03-01), Chester et al.
patent: 11251/92 (1993-01-01), None
patent: 2107513 (1994-04-01), None
patent: 0396387 (1990-11-01), None
patent: 0396387 (1990-11-01), None
patent: 0497585 (1992-08-01), None
patent: 0501215 (1992-09-01), None
patent: 0497585 (1993-05-01), None
patent: 0501215 (1993-08-01), None
patent: 0396387 (1993-12-01), None
patent: 0590530 (1994-04-01), None
patent: 0590530 (1997-03-01), None
patent: 0590530 (2000-04-01), None
patent: 0501215 (2000-05-01), None
patent: 920630 (1992-09-01), None
patent: 88/07378 (1988-10-01), None
patent: 91/01990 (1991-02-01), None
patent: 92/01059 (1992-01-01), None
patent: 92/15333 (1992-09-01), None
patent: 94/19466 (1994-09-01), None
patent: 95/15341 (1995-06-01), None
Kim et al. (Hybridoma, vol. 20(4), pp. 265-272, 2001) Abstract only.
Adams, et al. “High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules” Cancer Res. 61:4750-4755 (2001).
Baca et al. “Antibody humanization using monovalent phage display” J. Biol. Chem. 272:10678-10684 (1997).
Bagshawe et al. “Antibody-enzyme conjugates can generate cytotoxic drugs from inactive precursors at tumor sites” Antibody Immunocon. Radiopharm. 4:915-922 (1991).
Baulida et al. “All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired” J. Biol. Chem. 271:5251-5257 (1996).
Baxter et al. “Biodistribution of monoclonal antibodies: Scale-up from mouse to human using a physiologically based pharmacokinetic model” Cancer Res. 55:4611-4622 (1995).
Baxter et al. “Transport of fluid and macromolecules in tumors: III. Role of binding and metabolism” Microvasc. Res. 41:5-23 (1991).
Baxter et al. “Transport of fluid and macromolecules in tumors: IV. A microscopic model of the perivascular distribution” Microvasc. Res. 41:252-272 (1991).
Beers et al. “Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display” Clin. Cancer Res. 6:2835-2843 (2000).
Begent et al. “Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library” Nat. Med. 2:979-984 (1996).
Berk et al. “Direct in vivo measurement of targeted binding in a human tumor xenograft” Proc. Natl. Acad. Sci. USA, 94:1785-1790 (1997).
Bidart et al. “Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring” Clin. Chem. 45:1695-1707 (1999).
Boder et al. “Yeast surface display for screening combinatorial polypeptide libraries” Nat. Biotech. 15:553-557 (1997).
Boder et al. “Optimal screening of surface-displayed polypeptide libraries” Biotech. Prog. 14:55-62 (1998).
Boder et al. “Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity” Proc. Natl. Acad. Sci. USA 97:10701-10705 (2000).
Boehm et al. “Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts” Biochem. J. 346:519-528 (2000).
Boehm et al. “Structural models for carcinoembryonic antigen and its complex with the single-chain Fv antibody molecule MFE23” FEBS Lett. 475:11-16 (2000).
Bosslet et al. “Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy” Br. J. Cancer 63:681-686 (1991).
Boxer et al. “Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal carcinoma implications for radioimmunotherapy” Br. J. Cancer 65:825-831 (1992).
Burgess et al. “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue” J. Cell Biol. 111:2129-2138 (1990).
Casey et al. “Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography” J. lmmunol. Meth. 179:105-116 (1995).
Chester et al. “Phage libraries for generation of clinically useful antibodies” Lancet 343:455-456 (1994).
Chester et al. “Clinical applications of phage-derived sFvs and sFv fusion proteins” Dis. Markers,16:53-62 (2000).
Chester et al. “Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer” Cancer Chemother. Pharmacol. 46:S8-12 (2000).
Chester et al. “Production of a high affinity anti-CEA scFv for colorectal tumour targeting” Abstract T306 J. Cellular Biochem. S18 D198 abstract at Keystone Symposium Lake Tahoe, CA (1994).
Coleman et al. “Effects of amino acid sequence changes on antibody-antigen interactions” Res. lmmunol. 145:33-36 (1994).
Cooke et al. “In vivo tumor delivery of a recombinant single-chain Fv::tumor necrosis factor: a fusion protein” Bioconjug. Chem. 13:7-15 (2002).
Daugherty et al. “Quantitative analysis of the effect of the mutation frequency on the affinity maturation of single chain Fv antibodies” Proc. Natl. Acad. Sci. USA 97:2029-2034 (2000).
Drewinko et al. “New monoclonal antibodies against colon cancer-associated antigens” Cancer Res. 46:5137-5143 (1986).
Dvorak et al. “Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis” Am. J. Pathol. 146:1029-1039 (1995).
Fujimori et al. “Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab1)2, and Fab in tumors” Cancer Res. 49:5656-5663 (1989).
Fujimori et al. “A modeling analysis of monoclonal antibody percolation through tumors: A binding-site barrier” J. Nucl. Med. 31:1191-1198 (1990).
Gerlowski et al. “Microvascular permeability of normal and neoplastic tissues” Microvasc. Res. 31:288-305 (1986).
Gold et al. “Specific carcinoembryonic antigens of the human digestive system” J. Exp. Med. 122:467-481 (1965).
Goldenberg “Cancer imaging with CEA antibodies: Historical and current perspectives” Int. J. Biol. Markers 7:183-188 (1992).
Graham et al. “Post surgical surveillance of colon cancer” Ann. Surg. 228:59-63 (1998).
Green et al. “Mathematical model of antibody targeting: Important parameters defined using clinical data” Phys. Med. Biol. 45:1679-1693 (2000).
Groebe et al. “On the relation between size of necrosis and diameter of tumor spheroids” Int. J. Radiat. Oncol. Biol. Phys. 34:395-401 (1996).
Hammarstrom “The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues” Cancer Biol. 9:67-81 (1999).
Hammarstrom et al. “Antigenic sites in carcinoembryonic antigen” Cancer Res. 49:4852-4858 (1989).
Ibragimova et al. “Stability of the β-sheet of the WW domain: A molecular dynamics simulation study” Biophys. J. 77:2191-2198 (1999).
Jackson et al. “Antigen specificity and tumor targeting efficiency of a human carcinoembryonic antigen-specific scFv and affinity-matured derivatives” Br. J. Cancer 78:181-188 (1998).
Jain “Transport of molecules, particles, and cells in solid tumors” Annu. Rev. Biomed. Engin.1:241-263 (1999).
Juweid et al. “Micropharmacology of monoclonal antibodies in solid tumors: Direct exper

Affiliated with

Also associated with

Rating

Antibodies against tumor surface antigens does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies against tumor surface antigens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies against tumor surface antigens will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4078563